| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 146 | 2025 | 983 | 13.080 |
Why?
|
| Metalloporphyrins | 34 | 2021 | 101 | 4.450 |
Why?
|
| Smoking | 71 | 2025 | 1499 | 4.170 |
Why?
|
| Pulmonary Emphysema | 33 | 2024 | 275 | 4.140 |
Why?
|
| Superoxide Dismutase | 44 | 2024 | 342 | 3.880 |
Why?
|
| Tomography, X-Ray Computed | 49 | 2024 | 2515 | 2.620 |
Why?
|
| Genome-Wide Association Study | 56 | 2024 | 1327 | 2.480 |
Why?
|
| Genetic Predisposition to Disease | 52 | 2023 | 2276 | 2.430 |
Why?
|
| Antioxidants | 28 | 2023 | 558 | 2.140 |
Why?
|
| Lung | 66 | 2025 | 3927 | 2.110 |
Why?
|
| Forced Expiratory Volume | 42 | 2025 | 510 | 2.100 |
Why?
|
| Emphysema | 15 | 2024 | 109 | 2.030 |
Why?
|
| Smokers | 10 | 2024 | 138 | 1.840 |
Why?
|
| Genetic Loci | 16 | 2019 | 275 | 1.480 |
Why?
|
| Spirometry | 32 | 2025 | 257 | 1.390 |
Why?
|
| Polymorphism, Single Nucleotide | 39 | 2024 | 2063 | 1.240 |
Why?
|
| Space Flight | 3 | 2024 | 80 | 1.210 |
Why?
|
| Oxidative Stress | 22 | 2024 | 1266 | 1.200 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 3 | 2023 | 67 | 1.080 |
Why?
|
| Reactive Oxygen Species | 17 | 2021 | 596 | 1.040 |
Why?
|
| Middle Aged | 124 | 2025 | 31090 | 1.000 |
Why?
|
| Male | 156 | 2025 | 63512 | 0.940 |
Why?
|
| Vital Capacity | 20 | 2025 | 291 | 0.910 |
Why?
|
| Humans | 216 | 2025 | 129266 | 0.900 |
Why?
|
| Aged | 100 | 2025 | 22032 | 0.900 |
Why?
|
| Female | 144 | 2025 | 68551 | 0.860 |
Why?
|
| Pneumonia | 6 | 2021 | 616 | 0.850 |
Why?
|
| Severity of Illness Index | 34 | 2022 | 2740 | 0.790 |
Why?
|
| Retina | 2 | 2023 | 277 | 0.790 |
Why?
|
| Bronchitis, Chronic | 7 | 2019 | 19 | 0.770 |
Why?
|
| Respiratory Function Tests | 21 | 2020 | 583 | 0.740 |
Why?
|
| Disease Progression | 23 | 2025 | 2630 | 0.720 |
Why?
|
| Radiation-Protective Agents | 8 | 2017 | 26 | 0.710 |
Why?
|
| Extracellular Space | 12 | 2011 | 120 | 0.700 |
Why?
|
| Free Radical Scavengers | 6 | 2010 | 82 | 0.670 |
Why?
|
| Addison Disease | 1 | 2019 | 43 | 0.650 |
Why?
|
| Premature Birth | 2 | 2021 | 314 | 0.620 |
Why?
|
| Phenotype | 22 | 2023 | 3074 | 0.600 |
Why?
|
| Clinical Protocols | 1 | 2019 | 254 | 0.590 |
Why?
|
| Mice | 45 | 2024 | 16915 | 0.570 |
Why?
|
| Pulmonary Artery | 7 | 2021 | 1095 | 0.560 |
Why?
|
| Aged, 80 and over | 38 | 2022 | 7055 | 0.550 |
Why?
|
| Lung Diseases | 6 | 2015 | 739 | 0.540 |
Why?
|
| Risk Factors | 38 | 2023 | 9745 | 0.520 |
Why?
|
| Animals | 68 | 2024 | 35309 | 0.520 |
Why?
|
| Biomarkers | 14 | 2023 | 3968 | 0.500 |
Why?
|
| Asthma | 12 | 2019 | 2229 | 0.470 |
Why?
|
| Comorbidity | 12 | 2022 | 1544 | 0.460 |
Why?
|
| Quality of Life | 17 | 2023 | 2687 | 0.460 |
Why?
|
| Longitudinal Studies | 17 | 2023 | 2715 | 0.450 |
Why?
|
| Respiratory System | 5 | 2016 | 154 | 0.440 |
Why?
|
| Respiratory Tract Diseases | 3 | 2020 | 148 | 0.440 |
Why?
|
| Case-Control Studies | 21 | 2020 | 3377 | 0.440 |
Why?
|
| Vascular Diseases | 2 | 2021 | 240 | 0.430 |
Why?
|
| Prospective Studies | 17 | 2024 | 7123 | 0.410 |
Why?
|
| Genetic Markers | 6 | 2019 | 336 | 0.410 |
Why?
|
| Pulmonary Fibrosis | 5 | 2019 | 384 | 0.400 |
Why?
|
| Bronchial Hyperreactivity | 2 | 2003 | 105 | 0.390 |
Why?
|
| Pulmonary Alveoli | 7 | 2017 | 400 | 0.380 |
Why?
|
| Cohort Studies | 22 | 2023 | 5409 | 0.370 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 5 | 2019 | 633 | 0.370 |
Why?
|
| Mice, Inbred C57BL | 20 | 2024 | 5439 | 0.350 |
Why?
|
| Cross-Sectional Studies | 18 | 2024 | 5050 | 0.350 |
Why?
|
| Cognitive Dysfunction | 3 | 2021 | 346 | 0.350 |
Why?
|
| Guinea Pigs | 3 | 2019 | 157 | 0.330 |
Why?
|
| Receptors, Nicotinic | 5 | 2019 | 329 | 0.330 |
Why?
|
| Cartilage, Articular | 3 | 2024 | 292 | 0.330 |
Why?
|
| Catalysis | 5 | 2011 | 308 | 0.320 |
Why?
|
| Disease Models, Animal | 18 | 2016 | 4057 | 0.310 |
Why?
|
| Oxidation-Reduction | 10 | 2018 | 1028 | 0.310 |
Why?
|
| Mycobacterium | 1 | 2010 | 106 | 0.310 |
Why?
|
| Transforming Growth Factor beta2 | 2 | 2019 | 35 | 0.310 |
Why?
|
| GTPase-Activating Proteins | 6 | 2019 | 81 | 0.310 |
Why?
|
| Bronchopulmonary Dysplasia | 4 | 2011 | 378 | 0.310 |
Why?
|
| Rabbits | 5 | 2019 | 777 | 0.310 |
Why?
|
| Gene Expression | 8 | 2019 | 1466 | 0.300 |
Why?
|
| Macrophages | 5 | 2011 | 1484 | 0.300 |
Why?
|
| Genetic Variation | 6 | 2019 | 938 | 0.300 |
Why?
|
| Reactive Nitrogen Species | 3 | 2016 | 22 | 0.290 |
Why?
|
| Inflammation | 9 | 2019 | 2737 | 0.290 |
Why?
|
| Oxygen | 6 | 2018 | 915 | 0.280 |
Why?
|
| Quantitative Trait Loci | 8 | 2019 | 352 | 0.280 |
Why?
|
| Gene Expression Regulation | 7 | 2019 | 2537 | 0.280 |
Why?
|
| United States | 26 | 2019 | 13826 | 0.280 |
Why?
|
| Infarction, Middle Cerebral Artery | 2 | 2009 | 39 | 0.280 |
Why?
|
| Haplotypes | 1 | 2008 | 475 | 0.270 |
Why?
|
| Fibrinogen | 3 | 2024 | 163 | 0.270 |
Why?
|
| Models, Statistical | 3 | 2020 | 623 | 0.270 |
Why?
|
| Maze Learning | 3 | 2006 | 104 | 0.270 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2008 | 203 | 0.260 |
Why?
|
| Finland | 2 | 2021 | 90 | 0.260 |
Why?
|
| Bleomycin | 3 | 2012 | 242 | 0.260 |
Why?
|
| Memory Disorders | 2 | 2017 | 168 | 0.250 |
Why?
|
| Total Lung Capacity | 4 | 2020 | 33 | 0.250 |
Why?
|
| Gene Expression Regulation, Enzymologic | 4 | 2010 | 286 | 0.250 |
Why?
|
| Adult | 26 | 2021 | 35495 | 0.250 |
Why?
|
| Sepharose | 2 | 2006 | 33 | 0.250 |
Why?
|
| Acute Lung Injury | 1 | 2008 | 279 | 0.240 |
Why?
|
| Islets of Langerhans Transplantation | 3 | 2018 | 63 | 0.240 |
Why?
|
| Cluster Analysis | 5 | 2019 | 479 | 0.240 |
Why?
|
| Airway Remodeling | 4 | 2018 | 61 | 0.240 |
Why?
|
| Osteoarthritis, Hip | 1 | 2005 | 43 | 0.240 |
Why?
|
| Exome | 2 | 2016 | 220 | 0.240 |
Why?
|
| Machine Learning | 2 | 2020 | 442 | 0.230 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2054 | 0.230 |
Why?
|
| Heparin | 3 | 2005 | 253 | 0.230 |
Why?
|
| Tissue Fixation | 1 | 2004 | 34 | 0.230 |
Why?
|
| Polymorphism, Genetic | 5 | 2015 | 639 | 0.230 |
Why?
|
| Organ Preservation Solutions | 1 | 2004 | 45 | 0.230 |
Why?
|
| Apoptosis | 6 | 2018 | 2499 | 0.230 |
Why?
|
| Chemokines | 3 | 2017 | 226 | 0.230 |
Why?
|
| Sleep Wake Disorders | 2 | 2020 | 251 | 0.230 |
Why?
|
| Transcriptome | 3 | 2023 | 874 | 0.220 |
Why?
|
| Follow-Up Studies | 13 | 2022 | 4887 | 0.220 |
Why?
|
| Nerve Tissue Proteins | 5 | 2015 | 569 | 0.220 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2015 | 103 | 0.220 |
Why?
|
| Organ Preservation | 1 | 2004 | 94 | 0.220 |
Why?
|
| Drug Evaluation, Preclinical | 5 | 2013 | 171 | 0.220 |
Why?
|
| Chromosomes, Human, Pair 5 | 2 | 2015 | 28 | 0.220 |
Why?
|
| Carrier Proteins | 4 | 2017 | 742 | 0.220 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 2018 | 183 | 0.220 |
Why?
|
| Periodicals as Topic | 3 | 2020 | 204 | 0.220 |
Why?
|
| Thioredoxins | 1 | 2003 | 28 | 0.220 |
Why?
|
| Cigarette Smoking | 1 | 2025 | 91 | 0.220 |
Why?
|
| Mucus | 2 | 2014 | 77 | 0.210 |
Why?
|
| Interleukin-18 | 2 | 2011 | 237 | 0.210 |
Why?
|
| alpha 1-Antitrypsin | 2 | 2017 | 107 | 0.210 |
Why?
|
| Aging | 2 | 2005 | 1774 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2013 | 2011 | 0.210 |
Why?
|
| Interleukin-2 | 2 | 2009 | 437 | 0.210 |
Why?
|
| Photoreceptor Cells | 1 | 2023 | 16 | 0.210 |
Why?
|
| Nitric Oxide Synthase | 5 | 2009 | 237 | 0.210 |
Why?
|
| Bronchodilator Agents | 4 | 2016 | 243 | 0.210 |
Why?
|
| Predictive Value of Tests | 9 | 2020 | 1949 | 0.210 |
Why?
|
| Logistic Models | 9 | 2020 | 1985 | 0.210 |
Why?
|
| Molecular Epidemiology | 2 | 2019 | 63 | 0.200 |
Why?
|
| Skin | 3 | 2016 | 726 | 0.200 |
Why?
|
| Rats | 15 | 2013 | 5482 | 0.200 |
Why?
|
| Terminology as Topic | 1 | 2024 | 203 | 0.200 |
Why?
|
| Golgi Apparatus | 2 | 2004 | 100 | 0.200 |
Why?
|
| Extracellular Matrix | 5 | 2010 | 502 | 0.200 |
Why?
|
| Genotype | 8 | 2018 | 1835 | 0.200 |
Why?
|
| Whole Genome Sequencing | 2 | 2024 | 129 | 0.200 |
Why?
|
| Tobacco Products | 1 | 2023 | 110 | 0.190 |
Why?
|
| Brain Ischemia | 2 | 2002 | 321 | 0.190 |
Why?
|
| Subtilisins | 1 | 2002 | 10 | 0.190 |
Why?
|
| DNA Methylation | 3 | 2019 | 610 | 0.190 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2002 | 64 | 0.190 |
Why?
|
| Prostatic Neoplasms | 4 | 2012 | 1016 | 0.190 |
Why?
|
| Airway Obstruction | 1 | 2024 | 152 | 0.190 |
Why?
|
| Carotid Arteries | 2 | 2021 | 196 | 0.190 |
Why?
|
| Papio | 7 | 2011 | 91 | 0.190 |
Why?
|
| Administration, Cutaneous | 2 | 2019 | 124 | 0.190 |
Why?
|
| Gene Expression Profiling | 8 | 2023 | 1688 | 0.190 |
Why?
|
| Toxicity Tests | 2 | 2019 | 29 | 0.190 |
Why?
|
| Risk Assessment | 7 | 2020 | 3232 | 0.180 |
Why?
|
| Linear Models | 7 | 2018 | 819 | 0.180 |
Why?
|
| Belgium | 1 | 2021 | 12 | 0.180 |
Why?
|
| Linkage Disequilibrium | 5 | 2017 | 257 | 0.180 |
Why?
|
| Republic of Korea | 1 | 2021 | 29 | 0.180 |
Why?
|
| Poland | 1 | 2021 | 33 | 0.180 |
Why?
|
| Spain | 1 | 2021 | 34 | 0.180 |
Why?
|
| Sputum | 3 | 2013 | 301 | 0.180 |
Why?
|
| Exercise Tolerance | 5 | 2015 | 273 | 0.180 |
Why?
|
| Genetic Association Studies | 4 | 2018 | 361 | 0.180 |
Why?
|
| Japan | 1 | 2021 | 98 | 0.180 |
Why?
|
| Forecasting | 2 | 2022 | 359 | 0.180 |
Why?
|
| Germany | 1 | 2021 | 100 | 0.180 |
Why?
|
| Sweden | 1 | 2021 | 93 | 0.180 |
Why?
|
| Iron Regulatory Protein 2 | 3 | 2015 | 6 | 0.180 |
Why?
|
| Intraocular Pressure | 1 | 2023 | 297 | 0.180 |
Why?
|
| Nitric Oxide | 5 | 2008 | 901 | 0.180 |
Why?
|
| Computed Tomography Angiography | 2 | 2021 | 114 | 0.180 |
Why?
|
| Data Collection | 2 | 2015 | 647 | 0.170 |
Why?
|
| Neoplasms | 2 | 2006 | 2449 | 0.170 |
Why?
|
| Mice, Transgenic | 8 | 2015 | 2117 | 0.170 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 110 | 0.170 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2003 | 610 | 0.170 |
Why?
|
| Desmoplakins | 2 | 2019 | 19 | 0.170 |
Why?
|
| Blood Vessels | 2 | 2013 | 187 | 0.170 |
Why?
|
| Swine | 3 | 2019 | 760 | 0.170 |
Why?
|
| Blood Flow Velocity | 3 | 2017 | 406 | 0.170 |
Why?
|
| Canada | 1 | 2021 | 350 | 0.170 |
Why?
|
| Carotid Artery Diseases | 1 | 2020 | 64 | 0.170 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2019 | 157 | 0.170 |
Why?
|
| Cytokines | 4 | 2017 | 2013 | 0.160 |
Why?
|
| Tyrosine | 3 | 2005 | 223 | 0.160 |
Why?
|
| Biomimetic Materials | 2 | 2018 | 69 | 0.160 |
Why?
|
| Thyroid Diseases | 1 | 2019 | 35 | 0.160 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2022 | 204 | 0.160 |
Why?
|
| Hyperostosis, Diffuse Idiopathic Skeletal | 1 | 2019 | 4 | 0.160 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2019 | 17 | 0.160 |
Why?
|
| Lymphoma | 2 | 2012 | 196 | 0.160 |
Why?
|
| Activin Receptors, Type I | 1 | 2019 | 7 | 0.160 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2019 | 22 | 0.160 |
Why?
|
| Rats, Sprague-Dawley | 8 | 2013 | 2396 | 0.160 |
Why?
|
| Swine, Miniature | 1 | 2019 | 81 | 0.160 |
Why?
|
| Environmental Exposure | 1 | 2003 | 462 | 0.160 |
Why?
|
| Brain | 5 | 2023 | 2669 | 0.150 |
Why?
|
| Macaca fascicularis | 2 | 2016 | 62 | 0.150 |
Why?
|
| Genome, Human | 4 | 2019 | 392 | 0.150 |
Why?
|
| Global Health | 1 | 2021 | 327 | 0.150 |
Why?
|
| Prevalence | 6 | 2023 | 2553 | 0.150 |
Why?
|
| Hypoxia | 3 | 2016 | 1084 | 0.150 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 162 | 0.150 |
Why?
|
| Blood Pressure | 4 | 2009 | 1736 | 0.150 |
Why?
|
| Psoriasis | 1 | 2019 | 87 | 0.150 |
Why?
|
| Infant, Newborn | 6 | 2021 | 5736 | 0.150 |
Why?
|
| Causality | 1 | 2019 | 118 | 0.150 |
Why?
|
| Hemorrhage | 1 | 2003 | 678 | 0.150 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2018 | 119 | 0.150 |
Why?
|
| Dexamethasone | 2 | 2012 | 350 | 0.150 |
Why?
|
| Pectoralis Muscles | 1 | 2018 | 17 | 0.150 |
Why?
|
| Phagocytosis | 2 | 2011 | 362 | 0.150 |
Why?
|
| Epidemiologic Studies | 2 | 2015 | 65 | 0.150 |
Why?
|
| Ventricular Function, Right | 2 | 2017 | 276 | 0.150 |
Why?
|
| Surveys and Questionnaires | 11 | 2022 | 5384 | 0.150 |
Why?
|
| DNA Copy Number Variations | 2 | 2016 | 168 | 0.150 |
Why?
|
| Critical Care | 2 | 2020 | 551 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 4 | 3 | 2015 | 29 | 0.140 |
Why?
|
| Down-Regulation | 4 | 2010 | 636 | 0.140 |
Why?
|
| Acetylcysteine | 2 | 2010 | 146 | 0.140 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2019 | 253 | 0.140 |
Why?
|
| Cellular Senescence | 1 | 2019 | 181 | 0.140 |
Why?
|
| Aorta | 6 | 2012 | 408 | 0.140 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2017 | 66 | 0.140 |
Why?
|
| Enzyme Activation | 5 | 2012 | 812 | 0.140 |
Why?
|
| Hydrocortisone | 1 | 2019 | 306 | 0.140 |
Why?
|
| Heart | 2 | 2015 | 637 | 0.140 |
Why?
|
| Multivariate Analysis | 6 | 2017 | 1497 | 0.140 |
Why?
|
| Mice, Inbred BALB C | 4 | 2018 | 1247 | 0.140 |
Why?
|
| Databases, Genetic | 1 | 2018 | 230 | 0.140 |
Why?
|
| Monocytes | 2 | 2011 | 551 | 0.140 |
Why?
|
| Proteins | 3 | 2010 | 941 | 0.140 |
Why?
|
| Gene Regulatory Networks | 2 | 2017 | 280 | 0.140 |
Why?
|
| Hemizygote | 1 | 2016 | 3 | 0.130 |
Why?
|
| Catalase | 4 | 2010 | 128 | 0.130 |
Why?
|
| Glucocorticoids | 2 | 2019 | 578 | 0.130 |
Why?
|
| Neuropsychological Tests | 2 | 2021 | 1014 | 0.130 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2021 | 275 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2016 | 48 | 0.130 |
Why?
|
| Immunohistochemistry | 6 | 2011 | 1691 | 0.130 |
Why?
|
| Gene Frequency | 4 | 2024 | 502 | 0.130 |
Why?
|
| Interleukin-27 | 1 | 2016 | 13 | 0.130 |
Why?
|
| Health Status | 4 | 2014 | 754 | 0.130 |
Why?
|
| Mutagenicity Tests | 1 | 2016 | 8 | 0.130 |
Why?
|
| Pruritus | 1 | 2016 | 58 | 0.130 |
Why?
|
| Free Radicals | 2 | 2009 | 105 | 0.130 |
Why?
|
| Liver | 4 | 2024 | 1839 | 0.130 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 2 | 2019 | 48 | 0.130 |
Why?
|
| Uteroglobin | 2 | 2013 | 23 | 0.130 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2016 | 61 | 0.130 |
Why?
|
| Attention | 1 | 2019 | 438 | 0.130 |
Why?
|
| Time Factors | 10 | 2020 | 6543 | 0.130 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 2 | 2013 | 35 | 0.130 |
Why?
|
| Host-Pathogen Interactions | 1 | 2019 | 351 | 0.130 |
Why?
|
| Respiratory Mechanics | 2 | 2013 | 64 | 0.130 |
Why?
|
| Radiation Injuries | 1 | 2017 | 135 | 0.130 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2017 | 742 | 0.130 |
Why?
|
| Cell Line | 5 | 2016 | 2779 | 0.130 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 426 | 0.130 |
Why?
|
| Endothelins | 1 | 2016 | 62 | 0.120 |
Why?
|
| Maximum Tolerated Dose | 1 | 2016 | 193 | 0.120 |
Why?
|
| Cognition | 2 | 2021 | 1122 | 0.120 |
Why?
|
| HLA-DRB1 Chains | 1 | 2016 | 108 | 0.120 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2017 | 234 | 0.120 |
Why?
|
| Dermatitis, Atopic | 1 | 2019 | 319 | 0.120 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2016 | 70 | 0.120 |
Why?
|
| Disease Management | 1 | 2019 | 588 | 0.120 |
Why?
|
| Chromosome Deletion | 1 | 2015 | 104 | 0.120 |
Why?
|
| Dyspnea | 4 | 2024 | 239 | 0.120 |
Why?
|
| Cells, Cultured | 6 | 2018 | 4077 | 0.120 |
Why?
|
| Bronchoalveolar Lavage Fluid | 6 | 2011 | 644 | 0.120 |
Why?
|
| Cadherins | 1 | 2017 | 188 | 0.120 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 632 | 0.120 |
Why?
|
| Galactosylceramidase | 1 | 2015 | 3 | 0.120 |
Why?
|
| Eye | 1 | 2016 | 104 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 2439 | 0.120 |
Why?
|
| RNA, Messenger | 7 | 2014 | 2703 | 0.120 |
Why?
|
| Health Planning Guidelines | 1 | 2015 | 25 | 0.120 |
Why?
|
| Epidemiologic Research Design | 1 | 2015 | 27 | 0.120 |
Why?
|
| Heart Rate | 2 | 2016 | 802 | 0.120 |
Why?
|
| Mouth Mucosa | 1 | 2015 | 89 | 0.120 |
Why?
|
| Vascular Stiffness | 1 | 2020 | 467 | 0.120 |
Why?
|
| Axonemal Dyneins | 1 | 2014 | 9 | 0.120 |
Why?
|
| Molecular Mimicry | 3 | 2003 | 38 | 0.120 |
Why?
|
| Research Design | 2 | 2019 | 1043 | 0.120 |
Why?
|
| Hematologic Diseases | 1 | 2015 | 61 | 0.120 |
Why?
|
| Islets of Langerhans | 2 | 2018 | 789 | 0.110 |
Why?
|
| Prognosis | 5 | 2020 | 3773 | 0.110 |
Why?
|
| Chemokines, CC | 1 | 2014 | 33 | 0.110 |
Why?
|
| Blood Proteins | 1 | 2016 | 244 | 0.110 |
Why?
|
| Matrix Attachment Region Binding Proteins | 1 | 2014 | 4 | 0.110 |
Why?
|
| Computational Biology | 2 | 2016 | 595 | 0.110 |
Why?
|
| Tobacco Smoke Pollution | 3 | 2011 | 231 | 0.110 |
Why?
|
| Fibroblasts | 1 | 2019 | 948 | 0.110 |
Why?
|
| Respiratory Insufficiency | 1 | 2017 | 313 | 0.110 |
Why?
|
| Occupational Exposure | 2 | 2014 | 299 | 0.110 |
Why?
|
| Spinal Fractures | 1 | 2015 | 82 | 0.110 |
Why?
|
| Proctitis | 1 | 2013 | 6 | 0.110 |
Why?
|
| Bronchitis | 2 | 2015 | 43 | 0.110 |
Why?
|
| Health Status Indicators | 1 | 2014 | 167 | 0.110 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 428 | 0.110 |
Why?
|
| Myocardial Reperfusion Injury | 2 | 2006 | 129 | 0.110 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 124 | 0.110 |
Why?
|
| Radiography, Thoracic | 4 | 2015 | 166 | 0.110 |
Why?
|
| Alleles | 4 | 2017 | 845 | 0.110 |
Why?
|
| Chromosome Mapping | 4 | 2015 | 504 | 0.110 |
Why?
|
| Psychometrics | 1 | 2017 | 691 | 0.100 |
Why?
|
| Pamphlets | 1 | 2013 | 23 | 0.100 |
Why?
|
| Idiopathic Interstitial Pneumonias | 1 | 2013 | 49 | 0.100 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 321 | 0.100 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2013 | 42 | 0.100 |
Why?
|
| Glutathione Peroxidase | 2 | 2010 | 43 | 0.100 |
Why?
|
| Superoxides | 3 | 2008 | 201 | 0.100 |
Why?
|
| Reproducibility of Results | 5 | 2024 | 3080 | 0.100 |
Why?
|
| Dendritic Cells | 3 | 2016 | 479 | 0.100 |
Why?
|
| Receptors, Serotonin, 5-HT4 | 1 | 2012 | 1 | 0.100 |
Why?
|
| Regression Analysis | 4 | 2018 | 991 | 0.100 |
Why?
|
| Myocardial Ischemia | 2 | 2005 | 258 | 0.100 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2012 | 19 | 0.100 |
Why?
|
| Cost of Illness | 1 | 2014 | 277 | 0.100 |
Why?
|
| Glycine | 2 | 2005 | 165 | 0.100 |
Why?
|
| Heart Ventricles | 1 | 2017 | 781 | 0.100 |
Why?
|
| Congresses as Topic | 1 | 2014 | 216 | 0.100 |
Why?
|
| Graft Survival | 2 | 2018 | 511 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 899 | 0.100 |
Why?
|
| Hypertension | 2 | 2019 | 1242 | 0.100 |
Why?
|
| Physical Conditioning, Animal | 1 | 2015 | 229 | 0.100 |
Why?
|
| Elastin | 3 | 2010 | 77 | 0.100 |
Why?
|
| Primary Prevention | 1 | 2014 | 188 | 0.100 |
Why?
|
| Telecommunications | 1 | 2012 | 20 | 0.100 |
Why?
|
| Kidney | 3 | 2016 | 1385 | 0.100 |
Why?
|
| Rectum | 1 | 2013 | 170 | 0.100 |
Why?
|
| Osteoporosis | 1 | 2015 | 229 | 0.100 |
Why?
|
| Multigene Family | 1 | 2013 | 199 | 0.100 |
Why?
|
| Thymus Neoplasms | 1 | 2012 | 22 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 947 | 0.100 |
Why?
|
| Computers | 2 | 2022 | 65 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 543 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2011 | 23 | 0.090 |
Why?
|
| Protons | 1 | 2012 | 80 | 0.090 |
Why?
|
| Body Mass Index | 4 | 2017 | 2272 | 0.090 |
Why?
|
| Arginine | 2 | 2005 | 265 | 0.090 |
Why?
|
| Registries | 1 | 2019 | 1895 | 0.090 |
Why?
|
| Interleukin-8 | 2 | 2012 | 262 | 0.090 |
Why?
|
| Research | 1 | 2015 | 416 | 0.090 |
Why?
|
| Gastroesophageal Reflux | 1 | 2014 | 232 | 0.090 |
Why?
|
| Cell Line, Tumor | 6 | 2019 | 3202 | 0.090 |
Why?
|
| Radiotherapy | 1 | 2012 | 185 | 0.090 |
Why?
|
| Dopamine beta-Hydroxylase | 1 | 2011 | 13 | 0.090 |
Why?
|
| Animals, Newborn | 4 | 2009 | 834 | 0.090 |
Why?
|
| Protein Folding | 3 | 2008 | 264 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2015 | 350 | 0.090 |
Why?
|
| Biomedical Research | 2 | 2011 | 637 | 0.090 |
Why?
|
| Leukocyte Elastase | 1 | 2011 | 74 | 0.090 |
Why?
|
| NF-kappa B | 3 | 2011 | 665 | 0.090 |
Why?
|
| Bone Density | 1 | 2015 | 462 | 0.090 |
Why?
|
| Collagen | 2 | 2005 | 433 | 0.090 |
Why?
|
| Chronic Disease | 4 | 2014 | 1716 | 0.090 |
Why?
|
| Radiography | 4 | 2015 | 796 | 0.090 |
Why?
|
| Neutrophils | 4 | 2010 | 1207 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2018 | 1269 | 0.090 |
Why?
|
| Walking | 2 | 2015 | 498 | 0.090 |
Why?
|
| Mycobacterium avium Complex | 1 | 2011 | 88 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 15 | 3 | 2015 | 56 | 0.090 |
Why?
|
| Aconitate Hydratase | 3 | 2009 | 17 | 0.090 |
Why?
|
| Microbial Viability | 1 | 2011 | 83 | 0.090 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2011 | 61 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2012 | 1202 | 0.090 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 2010 | 17 | 0.090 |
Why?
|
| International Cooperation | 1 | 2011 | 174 | 0.090 |
Why?
|
| Inflammasomes | 1 | 2012 | 126 | 0.090 |
Why?
|
| Radiology | 1 | 2012 | 159 | 0.080 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2010 | 23 | 0.080 |
Why?
|
| Mycobacterium Infections | 1 | 2010 | 62 | 0.080 |
Why?
|
| Radiotherapy, Conformal | 1 | 2010 | 69 | 0.080 |
Why?
|
| Interleukins | 1 | 2011 | 241 | 0.080 |
Why?
|
| Self Report | 1 | 2014 | 795 | 0.080 |
Why?
|
| Hemodynamics | 3 | 2004 | 1090 | 0.080 |
Why?
|
| Rest | 3 | 2016 | 120 | 0.080 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2011 | 143 | 0.080 |
Why?
|
| Porphyrins | 1 | 2009 | 21 | 0.080 |
Why?
|
| Depression | 1 | 2018 | 1306 | 0.080 |
Why?
|
| Child | 5 | 2021 | 20785 | 0.080 |
Why?
|
| Endocytosis | 1 | 2010 | 163 | 0.080 |
Why?
|
| Organ Size | 4 | 2016 | 446 | 0.080 |
Why?
|
| Molecular Sequence Data | 5 | 2008 | 2835 | 0.080 |
Why?
|
| Proof of Concept Study | 2 | 2019 | 69 | 0.080 |
Why?
|
| Pregnancy | 1 | 2021 | 6390 | 0.080 |
Why?
|
| Phagosomes | 1 | 2008 | 42 | 0.080 |
Why?
|
| Hypertension, Pulmonary | 2 | 2017 | 1894 | 0.080 |
Why?
|
| Nutrition Surveys | 2 | 2024 | 260 | 0.080 |
Why?
|
| Oxidants | 2 | 2011 | 109 | 0.080 |
Why?
|
| Tobacco Use Disorder | 1 | 2011 | 236 | 0.070 |
Why?
|
| Environment | 1 | 2010 | 344 | 0.070 |
Why?
|
| Smoking Prevention | 1 | 2009 | 163 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2009 | 839 | 0.070 |
Why?
|
| Macrophages, Alveolar | 1 | 2011 | 389 | 0.070 |
Why?
|
| Neuroprotective Agents | 1 | 2009 | 122 | 0.070 |
Why?
|
| Lysosomes | 1 | 2008 | 137 | 0.070 |
Why?
|
| Odds Ratio | 3 | 2016 | 1019 | 0.070 |
Why?
|
| Hospitalization | 2 | 2014 | 2052 | 0.070 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2005 | 171 | 0.070 |
Why?
|
| Gastrin-Releasing Peptide | 1 | 2007 | 7 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 2 | 2012 | 1497 | 0.070 |
Why?
|
| Bombesin | 1 | 2007 | 11 | 0.070 |
Why?
|
| RNA | 3 | 2019 | 880 | 0.070 |
Why?
|
| Incidence | 4 | 2015 | 2636 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 430 | 0.070 |
Why?
|
| Age Factors | 4 | 2019 | 3140 | 0.070 |
Why?
|
| Walk Test | 2 | 2018 | 70 | 0.070 |
Why?
|
| Enzyme Inhibitors | 4 | 2006 | 827 | 0.070 |
Why?
|
| Structure-Activity Relationship | 3 | 2003 | 548 | 0.070 |
Why?
|
| Europe | 2 | 2019 | 363 | 0.070 |
Why?
|
| Treatment Outcome | 8 | 2017 | 10202 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2008 | 350 | 0.070 |
Why?
|
| Cause of Death | 2 | 2020 | 392 | 0.070 |
Why?
|
| Amino Acid Sequence | 4 | 2005 | 2056 | 0.070 |
Why?
|
| Escherichia coli | 1 | 2011 | 766 | 0.070 |
Why?
|
| Epithelial Cells | 2 | 2011 | 1063 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 1197 | 0.070 |
Why?
|
| Mice, Knockout | 4 | 2011 | 2871 | 0.070 |
Why?
|
| Exercise Test | 3 | 2015 | 612 | 0.070 |
Why?
|
| Journalism, Medical | 1 | 2006 | 5 | 0.070 |
Why?
|
| T-Lymphocytes | 3 | 2007 | 1933 | 0.070 |
Why?
|
| Protein Subunits | 1 | 2007 | 234 | 0.070 |
Why?
|
| Smoke | 2 | 2010 | 139 | 0.060 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2006 | 46 | 0.060 |
Why?
|
| Body Weight | 5 | 2010 | 939 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 2 | 2021 | 1708 | 0.060 |
Why?
|
| Models, Biological | 3 | 2016 | 1722 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 1000 | 0.060 |
Why?
|
| Estrogens | 1 | 2009 | 346 | 0.060 |
Why?
|
| Mitochondria | 1 | 2012 | 877 | 0.060 |
Why?
|
| Propensity Score | 2 | 2019 | 263 | 0.060 |
Why?
|
| Tobacco Industry | 1 | 2006 | 46 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 3 | 2004 | 841 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2006 | 72 | 0.060 |
Why?
|
| Cytochrome P-450 CYP2A6 | 2 | 2019 | 9 | 0.060 |
Why?
|
| Mice, Inbred CBA | 1 | 2005 | 52 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2005 | 4926 | 0.060 |
Why?
|
| Lipid Peroxidation | 2 | 2003 | 151 | 0.060 |
Why?
|
| Mutation | 4 | 2018 | 3710 | 0.060 |
Why?
|
| Head Injuries, Closed | 1 | 2006 | 49 | 0.060 |
Why?
|
| Subcellular Fractions | 1 | 2005 | 80 | 0.060 |
Why?
|
| Analysis of Variance | 3 | 2014 | 1288 | 0.060 |
Why?
|
| Femur Head | 1 | 2005 | 36 | 0.060 |
Why?
|
| Estradiol | 1 | 2009 | 494 | 0.060 |
Why?
|
| Nitrates | 1 | 2005 | 88 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 1 | 2007 | 296 | 0.060 |
Why?
|
| PPAR alpha | 1 | 2005 | 58 | 0.060 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2002 | 135 | 0.060 |
Why?
|
| Dimerization | 4 | 2007 | 191 | 0.060 |
Why?
|
| Hindlimb | 1 | 2005 | 122 | 0.060 |
Why?
|
| Mothers | 1 | 2011 | 730 | 0.060 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2004 | 327 | 0.060 |
Why?
|
| Oximetry | 2 | 2016 | 87 | 0.060 |
Why?
|
| Cell Division | 2 | 2004 | 796 | 0.060 |
Why?
|
| Glutaral | 1 | 2004 | 15 | 0.060 |
Why?
|
| Proteomics | 2 | 2023 | 1054 | 0.060 |
Why?
|
| Intercellular Junctions | 1 | 2004 | 39 | 0.060 |
Why?
|
| CpG Islands | 2 | 2015 | 152 | 0.060 |
Why?
|
| NADPH Oxidases | 1 | 2005 | 108 | 0.060 |
Why?
|
| Formaldehyde | 1 | 2004 | 60 | 0.060 |
Why?
|
| Weightlessness | 1 | 2024 | 41 | 0.060 |
Why?
|
| X-Ray Microtomography | 1 | 2024 | 83 | 0.060 |
Why?
|
| Interleukin-6 | 2 | 2012 | 720 | 0.060 |
Why?
|
| DNA | 1 | 2011 | 1396 | 0.060 |
Why?
|
| Immunochemistry | 1 | 2004 | 13 | 0.060 |
Why?
|
| Menisci, Tibial | 1 | 2024 | 59 | 0.060 |
Why?
|
| Tomography, Spiral Computed | 2 | 2014 | 27 | 0.060 |
Why?
|
| Tibia | 1 | 2005 | 170 | 0.060 |
Why?
|
| Injections | 1 | 2004 | 174 | 0.060 |
Why?
|
| Cough | 2 | 2016 | 116 | 0.060 |
Why?
|
| Executive Function | 2 | 2020 | 431 | 0.060 |
Why?
|
| Disease Susceptibility | 2 | 2017 | 333 | 0.050 |
Why?
|
| Retrospective Studies | 5 | 2022 | 14461 | 0.050 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2004 | 132 | 0.050 |
Why?
|
| Protein Binding | 3 | 2010 | 2120 | 0.050 |
Why?
|
| Weight-Bearing | 1 | 2024 | 162 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2019 | 776 | 0.050 |
Why?
|
| Stroke Volume | 2 | 2017 | 592 | 0.050 |
Why?
|
| Heart Failure | 1 | 2016 | 2135 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2004 | 166 | 0.050 |
Why?
|
| Collagen Type I | 1 | 2004 | 118 | 0.050 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2003 | 91 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2005 | 1204 | 0.050 |
Why?
|
| Chemotaxis | 1 | 2003 | 129 | 0.050 |
Why?
|
| Biomimetics | 1 | 2003 | 42 | 0.050 |
Why?
|
| X Chromosome | 1 | 2023 | 52 | 0.050 |
Why?
|
| Norway | 2 | 2014 | 42 | 0.050 |
Why?
|
| Chemokine CXCL2 | 1 | 2002 | 43 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2004 | 233 | 0.050 |
Why?
|
| Triglycerides | 1 | 2005 | 527 | 0.050 |
Why?
|
| Genotyping Techniques | 2 | 2014 | 72 | 0.050 |
Why?
|
| Myocardium | 2 | 2005 | 978 | 0.050 |
Why?
|
| Vasomotor System | 1 | 2002 | 44 | 0.050 |
Why?
|
| Chemokines, CXC | 1 | 2002 | 70 | 0.050 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2002 | 24 | 0.050 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2002 | 37 | 0.050 |
Why?
|
| Growth Substances | 1 | 2002 | 150 | 0.050 |
Why?
|
| Respiratory Mucosa | 1 | 2005 | 307 | 0.050 |
Why?
|
| Brefeldin A | 1 | 2002 | 10 | 0.050 |
Why?
|
| Principal Component Analysis | 1 | 2023 | 190 | 0.050 |
Why?
|
| Endotoxemia | 1 | 2003 | 86 | 0.050 |
Why?
|
| Furin | 1 | 2002 | 13 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2002 | 97 | 0.050 |
Why?
|
| Ovalbumin | 1 | 2002 | 178 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2014 | 359 | 0.050 |
Why?
|
| Mass Spectrometry | 2 | 2004 | 713 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2013 | 3628 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 2003 | 0.050 |
Why?
|
| Hyperoxia | 1 | 2003 | 90 | 0.050 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2002 | 44 | 0.050 |
Why?
|
| Heat-Shock Proteins | 1 | 2002 | 136 | 0.050 |
Why?
|
| CHO Cells | 1 | 2002 | 154 | 0.050 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2004 | 327 | 0.050 |
Why?
|
| Cricetinae | 1 | 2002 | 278 | 0.050 |
Why?
|
| Dogs | 1 | 2002 | 382 | 0.050 |
Why?
|
| Membrane Glycoproteins | 2 | 2015 | 476 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2002 | 399 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2002 | 123 | 0.050 |
Why?
|
| Age of Onset | 2 | 2014 | 496 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2002 | 315 | 0.050 |
Why?
|
| Seizures | 1 | 2005 | 401 | 0.050 |
Why?
|
| Smoking Cessation | 2 | 2018 | 405 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2003 | 288 | 0.050 |
Why?
|
| Molecular Structure | 1 | 2002 | 481 | 0.050 |
Why?
|
| Disulfides | 3 | 2008 | 97 | 0.050 |
Why?
|
| Carotid Artery, Common | 1 | 2021 | 35 | 0.040 |
Why?
|
| Endothelium, Vascular | 2 | 2004 | 901 | 0.040 |
Why?
|
| Drug Synergism | 2 | 2012 | 370 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2002 | 374 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 1 | 2002 | 227 | 0.040 |
Why?
|
| Skin Diseases | 1 | 2002 | 143 | 0.040 |
Why?
|
| Polymers | 1 | 2004 | 477 | 0.040 |
Why?
|
| Acute Disease | 2 | 2014 | 978 | 0.040 |
Why?
|
| C-Reactive Protein | 2 | 2013 | 400 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2002 | 756 | 0.040 |
Why?
|
| DNA Damage | 2 | 2013 | 383 | 0.040 |
Why?
|
| Genomics | 2 | 2018 | 717 | 0.040 |
Why?
|
| Reperfusion Injury | 1 | 2003 | 272 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2002 | 378 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 942 | 0.040 |
Why?
|
| Air | 1 | 2020 | 36 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 2 | 2012 | 285 | 0.040 |
Why?
|
| Lung Compliance | 2 | 2010 | 46 | 0.040 |
Why?
|
| Eosinophils | 1 | 2002 | 324 | 0.040 |
Why?
|
| rab4 GTP-Binding Proteins | 1 | 2019 | 9 | 0.040 |
Why?
|
| Anthropometry | 1 | 2020 | 204 | 0.040 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2019 | 9 | 0.040 |
Why?
|
| Hippocampus | 1 | 2005 | 871 | 0.040 |
Why?
|
| Cytochrome P450 Family 2 | 1 | 2019 | 12 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 1 | 2019 | 35 | 0.040 |
Why?
|
| Documentation | 1 | 2021 | 184 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein C | 1 | 2019 | 44 | 0.040 |
Why?
|
| Sleep Medicine Specialty | 1 | 2019 | 9 | 0.040 |
Why?
|
| Hydrogen Peroxide | 2 | 2012 | 318 | 0.040 |
Why?
|
| Bias | 1 | 2020 | 196 | 0.040 |
Why?
|
| Cardiomyopathies | 1 | 2003 | 340 | 0.040 |
Why?
|
| Jurkat Cells | 1 | 2019 | 134 | 0.040 |
Why?
|
| Exoribonucleases | 1 | 2019 | 43 | 0.040 |
Why?
|
| Temperature | 1 | 2002 | 634 | 0.040 |
Why?
|
| Epigenomics | 1 | 2019 | 110 | 0.040 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2019 | 133 | 0.040 |
Why?
|
| Education | 2 | 2012 | 100 | 0.040 |
Why?
|
| Colorado | 1 | 2008 | 4406 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 301 | 0.040 |
Why?
|
| Fetus | 1 | 2003 | 770 | 0.040 |
Why?
|
| Biofilms | 1 | 2021 | 243 | 0.040 |
Why?
|
| Pulmonary Medicine | 1 | 2019 | 79 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2021 | 381 | 0.040 |
Why?
|
| Telomere-Binding Proteins | 1 | 2019 | 102 | 0.040 |
Why?
|
| Systems Biology | 1 | 2018 | 59 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2019 | 149 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2018 | 284 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 385 | 0.040 |
Why?
|
| Adiponectin | 1 | 2019 | 235 | 0.030 |
Why?
|
| Self-Assessment | 1 | 2017 | 69 | 0.030 |
Why?
|
| Mucin-5B | 1 | 2019 | 214 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 327 | 0.030 |
Why?
|
| p-Methoxy-N-methylphenethylamine | 1 | 2016 | 4 | 0.030 |
Why?
|
| Telomerase | 1 | 2019 | 233 | 0.030 |
Why?
|
| Toluene 2,4-Diisocyanate | 1 | 2016 | 2 | 0.030 |
Why?
|
| Skin Cream | 1 | 2016 | 12 | 0.030 |
Why?
|
| Lipopolysaccharides | 3 | 2008 | 877 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2017 | 406 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 263 | 0.030 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2017 | 185 | 0.030 |
Why?
|
| Tissue Survival | 1 | 2016 | 16 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 412 | 0.030 |
Why?
|
| Ear | 1 | 2016 | 31 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2021 | 434 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2018 | 228 | 0.030 |
Why?
|
| Culture | 1 | 2017 | 124 | 0.030 |
Why?
|
| ABO Blood-Group System | 1 | 2016 | 39 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2016 | 51 | 0.030 |
Why?
|
| Boston | 1 | 2016 | 87 | 0.030 |
Why?
|
| Demography | 1 | 2017 | 279 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 395 | 0.030 |
Why?
|
| Spleen | 2 | 2009 | 506 | 0.030 |
Why?
|
| Metabolome | 1 | 2019 | 338 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2016 | 179 | 0.030 |
Why?
|
| Cytokinesis | 1 | 2016 | 48 | 0.030 |
Why?
|
| Mortality | 1 | 2018 | 307 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 485 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2016 | 212 | 0.030 |
Why?
|
| Myocardial Reperfusion | 2 | 2006 | 50 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2010 | 1199 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2003 | 1021 | 0.030 |
Why?
|
| Reaction Time | 1 | 2017 | 410 | 0.030 |
Why?
|
| Rats, Inbred F344 | 1 | 2016 | 259 | 0.030 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2015 | 31 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 892 | 0.030 |
Why?
|
| Amino Acid Substitution | 2 | 2008 | 282 | 0.030 |
Why?
|
| Serpins | 1 | 2015 | 31 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 117 | 0.030 |
Why?
|
| Microscopy, Immunoelectron | 2 | 2005 | 42 | 0.030 |
Why?
|
| Adolescent | 2 | 2018 | 20313 | 0.030 |
Why?
|
| Health Planning Councils | 1 | 2015 | 6 | 0.030 |
Why?
|
| Shock | 1 | 2016 | 92 | 0.030 |
Why?
|
| Diastole | 1 | 2015 | 148 | 0.030 |
Why?
|
| Keratinocytes | 1 | 2016 | 242 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 2003 | 790 | 0.030 |
Why?
|
| Muscle Strength | 1 | 2018 | 303 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2016 | 355 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 170 | 0.030 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 2014 | 14 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 2015 | 108 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 1204 | 0.030 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2014 | 30 | 0.030 |
Why?
|
| Protein Structure, Quaternary | 2 | 2006 | 122 | 0.030 |
Why?
|
| Vasoconstriction | 1 | 2016 | 199 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2014 | 56 | 0.030 |
Why?
|
| Chromatography, Affinity | 2 | 2005 | 83 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2016 | 372 | 0.030 |
Why?
|
| Base Sequence | 2 | 2008 | 2146 | 0.030 |
Why?
|
| alpha-Mannosidase | 1 | 2014 | 2 | 0.030 |
Why?
|
| snRNP Core Proteins | 1 | 2014 | 5 | 0.030 |
Why?
|
| Mannosidases | 1 | 2014 | 4 | 0.030 |
Why?
|
| Cardiac Catheterization | 1 | 2017 | 518 | 0.030 |
Why?
|
| Thiolester Hydrolases | 1 | 2014 | 13 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 785 | 0.030 |
Why?
|
| Manganese | 2 | 2006 | 59 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2018 | 529 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 304 | 0.030 |
Why?
|
| Interferon-gamma | 2 | 2011 | 772 | 0.030 |
Why?
|
| RNA Helicases | 1 | 2014 | 23 | 0.030 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2014 | 22 | 0.030 |
Why?
|
| Metabolomics | 1 | 2019 | 652 | 0.030 |
Why?
|
| Genetic Linkage | 1 | 2014 | 299 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 854 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1004 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2016 | 580 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2021 | 970 | 0.030 |
Why?
|
| Desmosine | 1 | 2013 | 6 | 0.030 |
Why?
|
| No-Observed-Adverse-Effect Level | 1 | 2013 | 4 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2013 | 147 | 0.030 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2013 | 74 | 0.030 |
Why?
|
| Foundations | 1 | 2013 | 24 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2014 | 176 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2013 | 41 | 0.030 |
Why?
|
| Hypercholesterolemia | 1 | 2014 | 102 | 0.030 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 2 | 2003 | 31 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 314 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2017 | 939 | 0.030 |
Why?
|
| Bronchi | 1 | 2014 | 247 | 0.030 |
Why?
|
| Radiographic Image Enhancement | 1 | 2013 | 54 | 0.030 |
Why?
|
| Health Services | 1 | 2013 | 99 | 0.030 |
Why?
|
| Glucose | 1 | 2018 | 1001 | 0.030 |
Why?
|
| Osteoarthritis | 1 | 2015 | 168 | 0.030 |
Why?
|
| Morbidity | 1 | 2013 | 300 | 0.030 |
Why?
|
| Observation | 1 | 2012 | 51 | 0.020 |
Why?
|
| Administration, Intravenous | 1 | 2013 | 141 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 480 | 0.020 |
Why?
|
| Angiography | 1 | 2013 | 196 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2013 | 148 | 0.020 |
Why?
|
| Penis | 1 | 2012 | 35 | 0.020 |
Why?
|
| Erectile Dysfunction | 1 | 2012 | 39 | 0.020 |
Why?
|
| Aortography | 1 | 2012 | 51 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2012 | 59 | 0.020 |
Why?
|
| Radiation, Ionizing | 1 | 2012 | 76 | 0.020 |
Why?
|
| Running | 1 | 2015 | 223 | 0.020 |
Why?
|
| Homeostasis | 1 | 2016 | 605 | 0.020 |
Why?
|
| Automation | 1 | 2012 | 81 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 616 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2015 | 295 | 0.020 |
Why?
|
| Testis | 1 | 2012 | 144 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2015 | 527 | 0.020 |
Why?
|
| Bronchospirometry | 1 | 2011 | 1 | 0.020 |
Why?
|
| Hemolysis | 1 | 2013 | 199 | 0.020 |
Why?
|
| Cardiovascular System | 1 | 2013 | 136 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2012 | 307 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2012 | 245 | 0.020 |
Why?
|
| Knee Joint | 1 | 2015 | 372 | 0.020 |
Why?
|
| Telephone | 1 | 2012 | 167 | 0.020 |
Why?
|
| Caspase 1 | 1 | 2012 | 143 | 0.020 |
Why?
|
| Algorithms | 1 | 2019 | 1613 | 0.020 |
Why?
|
| Observer Variation | 1 | 2012 | 315 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2011 | 118 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2013 | 253 | 0.020 |
Why?
|
| Intracellular Space | 1 | 2011 | 69 | 0.020 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2010 | 23 | 0.020 |
Why?
|
| Biopsy | 1 | 2014 | 1092 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2008 | 1416 | 0.020 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2012 | 149 | 0.020 |
Why?
|
| Pancreatic Elastase | 1 | 2010 | 60 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 696 | 0.020 |
Why?
|
| Heparitin Sulfate | 1 | 2010 | 42 | 0.020 |
Why?
|
| Hep G2 Cells | 1 | 2010 | 61 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2003 | 2342 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 117 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2010 | 166 | 0.020 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2010 | 22 | 0.020 |
Why?
|
| Glutathione | 1 | 2012 | 347 | 0.020 |
Why?
|
| COS Cells | 1 | 2010 | 186 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2010 | 132 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2010 | 305 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 192 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 514 | 0.020 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2010 | 37 | 0.020 |
Why?
|
| Plasma | 1 | 2011 | 205 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 1005 | 0.020 |
Why?
|
| Receptors, Estradiol | 1 | 2009 | 3 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 2010 | 98 | 0.020 |
Why?
|
| Lymphoma, Follicular | 1 | 2009 | 38 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2010 | 400 | 0.020 |
Why?
|
| Neuroglia | 1 | 2010 | 163 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2010 | 153 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2010 | 131 | 0.020 |
Why?
|
| Ductus Arteriosus | 1 | 2009 | 72 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 833 | 0.020 |
Why?
|
| Denmark | 1 | 2008 | 44 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2009 | 84 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2008 | 201 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 1839 | 0.020 |
Why?
|
| Gestational Age | 1 | 2011 | 874 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 1965 | 0.020 |
Why?
|
| Pulmonary Surfactants | 1 | 2009 | 106 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2010 | 207 | 0.020 |
Why?
|
| Random Allocation | 1 | 2009 | 346 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2009 | 441 | 0.020 |
Why?
|
| Internet | 1 | 2012 | 615 | 0.020 |
Why?
|
| Infant | 1 | 2021 | 8975 | 0.020 |
Why?
|
| Insulin | 1 | 2018 | 2325 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 768 | 0.020 |
Why?
|
| DNA Primers | 1 | 2008 | 510 | 0.020 |
Why?
|
| Leukocytes | 1 | 2009 | 306 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 915 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2007 | 326 | 0.020 |
Why?
|
| Body Composition | 1 | 2010 | 649 | 0.020 |
Why?
|
| Decision Making | 1 | 2013 | 849 | 0.020 |
Why?
|
| Rotarod Performance Test | 1 | 2006 | 16 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 530 | 0.020 |
Why?
|
| Heme Oxygenase-1 | 1 | 2006 | 62 | 0.020 |
Why?
|
| Peroxisomes | 1 | 2005 | 12 | 0.020 |
Why?
|
| Protein Carbonylation | 1 | 2006 | 56 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 2008 | 405 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 202 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2006 | 91 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 274 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2006 | 218 | 0.020 |
Why?
|
| Family | 1 | 2010 | 644 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2009 | 380 | 0.020 |
Why?
|
| Chromatography, Agarose | 1 | 2005 | 4 | 0.010 |
Why?
|
| Microvilli | 1 | 2005 | 79 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2007 | 336 | 0.010 |
Why?
|
| Neovascularization, Physiologic | 1 | 2006 | 175 | 0.010 |
Why?
|
| Caveolins | 1 | 2004 | 5 | 0.010 |
Why?
|
| Brain Injuries | 1 | 2010 | 466 | 0.010 |
Why?
|
| Caveolae | 1 | 2004 | 17 | 0.010 |
Why?
|
| Caveolin 1 | 1 | 2004 | 19 | 0.010 |
Why?
|
| Circular Dichroism | 1 | 2005 | 147 | 0.010 |
Why?
|
| Trypsin | 1 | 2004 | 74 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2005 | 426 | 0.010 |
Why?
|
| Carboxypeptidase B | 1 | 2004 | 2 | 0.010 |
Why?
|
| Carboxypeptidases | 1 | 2004 | 13 | 0.010 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2004 | 136 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2009 | 613 | 0.010 |
Why?
|
| Protein Transport | 1 | 2006 | 428 | 0.010 |
Why?
|
| Myosin Heavy Chains | 1 | 2005 | 170 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2007 | 427 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2004 | 110 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2005 | 368 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 2005 | 335 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2004 | 376 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2004 | 203 | 0.010 |
Why?
|
| Peptide Mapping | 1 | 2003 | 63 | 0.010 |
Why?
|
| Glycosylation | 1 | 2004 | 152 | 0.010 |
Why?
|
| Glyoxylates | 1 | 2003 | 9 | 0.010 |
Why?
|
| Thermodynamics | 1 | 2006 | 406 | 0.010 |
Why?
|
| Catalytic Domain | 1 | 2004 | 218 | 0.010 |
Why?
|
| Chondrocytes | 1 | 2005 | 203 | 0.010 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2004 | 179 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2005 | 541 | 0.010 |
Why?
|
| Cysteine | 1 | 2004 | 195 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2004 | 372 | 0.010 |
Why?
|
| Renal Blood Flow, Effective | 1 | 2003 | 2 | 0.010 |
Why?
|
| Erythrocytes | 1 | 2009 | 673 | 0.010 |
Why?
|
| Heterozygote | 1 | 2004 | 272 | 0.010 |
Why?
|
| Sulfonylurea Compounds | 1 | 2003 | 46 | 0.010 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2002 | 10 | 0.010 |
Why?
|
| Peroxynitrous Acid | 1 | 2002 | 14 | 0.010 |
Why?
|
| Microdialysis | 1 | 2002 | 51 | 0.010 |
Why?
|
| Instillation, Drug | 1 | 2002 | 9 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 2004 | 666 | 0.010 |
Why?
|
| Monokines | 1 | 2002 | 22 | 0.010 |
Why?
|
| Nitric Oxide Donors | 1 | 2002 | 19 | 0.010 |
Why?
|
| Rats, Inbred SHR | 1 | 2002 | 44 | 0.010 |
Why?
|
| Injections, Intraventricular | 1 | 2002 | 55 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2003 | 302 | 0.010 |
Why?
|
| Metaplasia | 1 | 2002 | 54 | 0.010 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2002 | 38 | 0.010 |
Why?
|
| Cerebral Infarction | 1 | 2002 | 42 | 0.010 |
Why?
|
| Pulmonary Circulation | 1 | 2004 | 430 | 0.010 |
Why?
|
| Carotid Artery, Internal | 1 | 2002 | 41 | 0.010 |
Why?
|
| Carbon Monoxide | 1 | 2002 | 68 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2002 | 148 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2004 | 263 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2006 | 436 | 0.010 |
Why?
|
| Respiratory Burst | 1 | 2002 | 15 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 12391 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2005 | 427 | 0.010 |
Why?
|
| Insulinoma | 1 | 2002 | 30 | 0.010 |
Why?
|
| Glutamic Acid | 1 | 2004 | 235 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2007 | 815 | 0.010 |
Why?
|
| Cell Count | 1 | 2002 | 311 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2007 | 746 | 0.010 |
Why?
|
| Antibodies | 1 | 2004 | 398 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2003 | 1085 | 0.010 |
Why?
|
| Antigen-Presenting Cells | 1 | 2002 | 151 | 0.010 |
Why?
|
| Clone Cells | 1 | 2002 | 262 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2002 | 220 | 0.010 |
Why?
|
| Neurons | 1 | 2010 | 1494 | 0.010 |
Why?
|
| Cattle | 1 | 2004 | 977 | 0.010 |
Why?
|
| Motor Activity | 1 | 2006 | 675 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2002 | 350 | 0.010 |
Why?
|
| Trachea | 1 | 2002 | 220 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 2002 | 148 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2006 | 1365 | 0.010 |
Why?
|
| Needs Assessment | 1 | 2003 | 359 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2004 | 692 | 0.010 |
Why?
|
| Fibrosis | 1 | 2003 | 520 | 0.010 |
Why?
|
| Mice, Inbred NOD | 1 | 2002 | 588 | 0.010 |
Why?
|
| Nicotine | 1 | 2002 | 302 | 0.010 |
Why?
|
| Echocardiography | 1 | 2003 | 629 | 0.010 |
Why?
|
| Ischemia | 1 | 2003 | 406 | 0.010 |
Why?
|
| Peptides | 1 | 2005 | 923 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2003 | 711 | 0.010 |
Why?
|
| Survival Rate | 1 | 2003 | 1869 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2002 | 704 | 0.010 |
Why?
|